Mirum Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Mirum Pharmaceuticals reported third-quarter 2026 net product sales of approximately $186 million, compared with $133 million in the third quarter last year; sales for the first nine months were approximately $522 million, equal to full-year 2025 revenues.
- Livemurley generated $133 million in third-quarter net product sales, including $100 million in the United States, while bioasset medicines generated $52 million.
- Atevrios was approved in September for adults and pediatric FOP patients ages 12 and older, and its U.S. launch commenced in October; management reported strong early engagement from patients, caregivers, and healthcare professionals.
- Cash used in operations was approximately $4 million, and cash, cash equivalents, and investments were approximately $500 million as of September.
- Total operating expenses for the quarter were approximately $245 million, including cost of sales of approximately $28 million, SG&A expense of approximately $70 million, R&D expense of approximately $94 million on a cash basis, in-process research and development of $13 million, and stock-based compensation, depreciation, and amortization expense of $40 million.
- Mirum repurchased $20 million in aggregate principal amount of its 2029 convertible notes for approximately $62 million in cash; the company said the transactions reduced the outstanding balance of its 2029 notes by over 80%.
- Management said quarterly revenues exceeded expectations, while expenses were unplanned.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, and welcome to Mirum Pharmaceuticals Third Quarter 2026 Earnings Conference Call. My name is Joel, and I will be your operator today. All lines are currently in a listen-only mode, and there will be an opportunity for Q&A after management's prepared remarks. I would now like to hand the conference over to Andrew McKibben, SVP of Strategic Finance and Investor Relations.
Please go ahead. Thank you, Joel, and good afternoon, everyone.
I'd like to welcome you to Mirum Pharmaceuticals Third Quarter 2026 Conference Call. I am joined today by our Chief Executive Officer, Chris Peetz, our President and Chief Operating Officer, Peter Radovich, our Chief Medical Officer, Rob Myers, and our Chief Financial Officer, Eric Bjerkholt. Earlier today, Mirum issued a press release announcing the company's results for the third quarter of 2026. Copies of the press release and our SEC filings are available on the Investors section of our website. Before we start, I'd like to remind you that during the course of this conference call, we will be making certain forward-looking statements based on management's current expectations, including statements regarding Mirum's programs and market opportunities for its approved medicines and product candidates, and financial guidance.
These statements represent our judgment and knowledge of events as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed. We are under no duty to update these statements. Please refer to the risk factors in our latest Form 10-Q and subsequent SEC filings for more information about these risks and uncertainties. With that, I'd like to turn the call over to Chris.
Chris? Thanks, Andrew. Third quarter was another strong period for Mirum, both commercially and across our clinical programs.
We generated $186 million in third quarter net product sales, and we are increasing our full year net product sales guidance to $715 million-$720 million. We have also had great progress across the portfolio since our last earnings call. Positive phase III AZURE-1 data for brelovitug, positive EXPAND data for LIVMARLI, the approval and launch of ATEBRIOZ, and another positive ATEBRIOZ readout in younger patients. Our recent progress feels quite meaningful as Mirum approaches its eighth anniversary. It is remarkable to think about what this team has accomplished in eight years. We started Mirum around a simple idea, that by identifying important opportunities in rare diseases and combining great medicines with relentless execution, we could have a meaningful impact for patients and build an enduring company.
Eight years later, we now have four approved medicines, a commercial business approaching three-quarters of a billion dollars in annual net product sales, and a late-stage pipeline with multiple opportunities to drive our next phase of growth. Coming up, we have two more potentially registrational readouts approaching, with the brelovitug AZURE-4 study in HDV expected this quarter and the volixibat VANTAGE study in PBC expected in the first quarter of next year. Together, these are part of five potential approvals and label expansions ahead of us as we work towards realizing the greater than $4 billion peak revenue potential of the Mirum portfolio. Eight years in, we're entering our next phase from a position of real strength, and we're excited to touch on some highlights and updates today. With that, I'll turn the call over to Peter.
Peter? Thanks, Chris. The third quarter was another excellent quarter for Mirum's commercial business, with $186 million in net product sales.
LIVMARLI continues to be the primary growth driver, with third quarter net product sales of $133 million, including $100 million in the U.S. Our bile acid medicines also provided steady growth, generating $52 million in net product sales for the quarter. Continued growth across LIVMARLI and our bile acid medicines has allowed us to increase that outlook throughout the year, and based on our performance through the first nine months, we are increasing full-year guidance today to $715 million-$720 million. This is a testament to our high-impact medicines and the high-performing team dedicated to getting them to patients. For a little more color on LIVMARLI, in Alagille syndrome, uptake remains steady and durable, supported by new patient starts, persistence on therapy, and weight-based dose increases.
PFIC continues to be an important driver, particularly among adults, where we believe there are at least 2,000 addressable patients in the U.S., though the substantial majority of these patients remain undiagnosed. Greater awareness of later-onset PFIC and increasing use of genetic testing will continue to help improve diagnosis rates, and we are expanding our commercial efforts on this front, which should lay a strong foundation for 2027. This expansion will also enable our other upcoming potential launches for LIVMARLI, volixibat, and brelovitug. I'm also happy to say that our fourth medicine, ATEBRIOZ, was approved in September for adults and pediatric FOP patients ages 12 and older, and our U.S. launch commenced in October. ATEBRIOZ is a natural addition to our rare genetic disease business.
The FOP community is uniquely engaged, and the response to the approval to date reinforces our belief that ATEBRIOZ can address a significant unmet need for patients and families living with FOP, with the convenience of oral dosing and a mechanism designed to address the underlying cause of the disease. Our near-term focus is on patient identification and access, and we're encouraged by the strong early engagement from patients, caregivers, and healthcare professionals. Overall, I'm very happy with the progress we made this quarter. We are growing our existing medicines, launching our fourth medicine, and laying a strong foundation for multiple new potential indications and launches in 2027 and beyond. With that, I'll turn it over to Rob.
Rob? Thanks, Peter. It's been an exciting couple of months for Mirum, with significant clinical progress across rare liver and rare genetic diseases.
We are now working towards five potential regulatory submissions across the portfolio: NDAs for volixibat in PSC and PBC, a BLA for brelovitug in hepatitis delta, a label expansion for ATEBRIOZ in FOP, and an sNDA for LIVMARLI based on the EXPAND study. Starting with volixibat in PSC, we continue to make progress toward our planned NDA submission in the first half of 2027. We remain confident in the strength of the VISTAS results and the potential for volixibat to address an important unmet need for patients with PSC and pruritus. We look forward to submitting our NDA and will provide an update if there's any material change in our plans or an FDA's prior feedback.
We've also recently reported positive results from three important studies across the portfolio. In FOP, cohort two of the pivotal PROGRESS study extended the encouraging ATEBRIOZ results into children ages six to under 12. The results were consistent with cohort one, with reductions in heterotopic ossification, encouraging improvements in joint mobility, and a safety profile consistent with that observed in older patients. The mobility findings are particularly encouraging in a progressive disease like FOP, where preserving function by intervening early is especially important. Our next step is the planned sNDA submission in the first half of 2027 to potentially expand ATEBRIOZ to children ages six to under 12. Cohort three, evaluating zilurgisertib in even younger children, continues to enroll. Now, turning to the liver portfolio, EXPAND was another positive phase III study for LIVMARLI, meeting its primary endpoint and all pre-specified secondary endpoints, with particularly encouraging results in biliary atresia.
These findings further strengthen the body of evidence supporting IBAT inhibition for pruritus across a range of underlying cholestatic liver diseases. In hepatitis delta, the positive phase III AZURE-1 results provide important validation for brelovitug, demonstrating meaningful improvements across key measures of virologic and liver disease activity. We'll build on this momentum at AASLD later this week, where we'll present new data across our rare liver disease portfolio, including the full AZURE-1 results and longer-term brelovitug data, as well as additional analyses from VISTAS and LIVMARLI data in rare cholestatic liver disease. Without getting ahead of these presentations, we're particularly excited by the growing body of evidence with brelovitug, showing deepening virologic suppression and continued improvements in ALT normalization and liver stiffness with longer treatment, including in patients with cirrhosis, a population with particularly urgent unmet medical needs.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
20 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
